



CLINICAL PROGRAM UPDATE

AURORA 2 / voclosporin

Updated January 2022




AURORA 2 Readout Results

AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy

AURORA 2 Study Design

- AURORA 2 is a Phase 3, global, double-blind, two-year continuation study of AURORA 1 evaluating voclosporin compared to placebo, in combination with MMF and low-dose steroids, in subjects with lupus nephritis
- This final analysis of AURORA 2 subjects includes integrated data from AURORA 1 and AURORA 2 with up to 36 months of total exposure



AURORA 2 Demographics

	Placebo n=% (n=100)	Voclosporin n=% (n=116)
Age, years		
Mean (SD)	11.64 (35.4)	10.31 (32.3)
Sex, n (%)		
Female	88.0 (88)	90.5 (105)
Male	12.0 (12)	9.5 (11)
Race, n (%)		
White	40.0 (40)	37.9 (44)
Asian	30.0 (30)	25.9 (30)
Black	7.0 (7)	15.5 (18)
Other	23.0 (23)	20.7 (24)
Biopsy class, n (%)		
Pure Class III or IV	58.0 (58)	67.2 (78)
Pure Class V	14.0 (14)	14.7 (17)
Mixed Class V	28.0 (28)	18.1 (21)
Region, n (%)		
North and Latin America	36.0 (36)	42.2 (49)
Europe and South Africa	37.0 (37)	32.8 (38)
Asia	27.0 (27)	25.0 (29)


AURORA 2 Clinical Characteristics

	Placebo n=100	Voclosporin n=116
Corrected* eGFR, mL/min/1.73 m², mean (SD)		
AURORA 1 Baseline	78.7 (16.58)	79.0 (15.05)
AURORA 2 Baseline (Month 12)	83.3 (12.61)	80.7 (13.53)
UPCR, mg/mg, mean (SD)		
AURORA 1 Baseline	3.868 (2.4764)	3.941 (2.5766)
AURORA 2 Baseline (Month 12)	1.47 (1.640)	0.86 (1.363)
AURORA 2 Baseline (Month 12) oral steroid dose		
Mean (SD), mg/day	3.395 (4.1104)	2.942 (3.3456)
≤2.5 mg/day, n (%)	85 (85.0)	102 (87.9)

AURORA 2 subject characteristics at pre-treatment baseline of AURORA 1 and baseline of AURORA 2.


*Renal function assessed with corrected eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) using a prespecified ceiling of 90 mL/min/1.73 m².

Corrected eGFR (mL/min/1.73m², mean) Over Time



* Number of patients in study arm

Mean UPCR by visit



* Number of patients in study arm

Summary of AURORA 2 Adverse Events

	Placebo (N = 100)	Voclosporin (N = 116)
	% (n)	% (n)
Any AE	80.0 (80)	86.2 (100)
Treatment-Related AE	21.0 (21)	24.1 (28)
Serious AE	23.0 (23)	18.1 (21)
Treatment-Related Serious AE	2.0 (2)	0.9 (1)
AE Leading to voclosporin/Placebo Discontinuation	17.0 (17)	9.5 (11)
Deaths	4.0 (4)	0
Disease-Related AE	34.0 (34)	43.1 (50)
Disease-Related Serious AE	11.0 (11)	6.0 (7)

AURORA 2 Readout Results

AURORA 2 demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy



Thank you

Trademarks are the property of Aurinia Pharmaceuticals Inc.
© 2021 Aurinia Pharmaceuticals Inc. All rights reserved.

